fda compounding semaglutide warning 2025 october Patient Safety Updates FDA Issues Warning: Compounding Certain

Semaglutide is a medication that mimics the effect of GLP-1, a hormone produced in your gut after you eat, and it has several effects on your body, such as: Stimulating insulin secretion and lowering blood sugar levels Slowing down gastric emptying and reducing food intake Increasing energy expenditure and fat-burning Reducing appetite and hunger Enhancing satiety and fullness Semaglutide was originally approved by the FDA as a treatment for type 2 diabetes, and in 2021, it was approved for chronic weight management in adults

Magorzewicz S, Gazowska G, Cieszyska-Semenowicz M, Ratajczyk J, Wolska L, Rutkowski P, et al

The results showed that tirzepatide led to significant and sustained reductions in body weight

What sets retatrutide apart is that it mimics the behaviour of three hormonesGLP-1, GIP and GCGrather than two (Mounjaro) or one (Wegovy)